Sight Sciences, Inc.
SGHTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeSight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in. The company carries a $460.0M market cap, placing it firmly in the small-cap category. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Market Cap
$460.0M
Beta
2.50
P/E (TTM)
—
P/E (Fwd)
-19.32
EPS (TTM)
$-0.55
EPS (Fwd)
$-0.43
ROE
-48.4%
ROA
-10.8%
Cash
$79.8M
Total Debt
$42.0M
Free CF
-$8.6M
52W Change
133.9%
Annual Financials
Cash vs Debt
Where SGHT stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, SGHT finished 63.15% above its 150-day moving average ($5.21) and 45.80% above its 200-day moving average ($5.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SGHT overbought or oversold?
At the September 1, 2026 close, SGHT's RSI(14) was 68.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $79.8M in cash comfortably exceeding the $42.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$8.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $71.3M (2022) to $77.4M (2025).
Sight Sciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SGHT.